Navigation Links
New drug strategy attacks resistant leukemia and lymphoma
Date:5/29/2012

BOSTON--Scientists at the Dana-Farber/Children's Hospital Cancer Center have developed an anti-cancer peptide that overcomes the stubborn resistance to chemotherapy and radiation often encountered in certain blood cancers when the disease recurs following initial treatment.

The strategy could pave the way for much needed new therapies to treat relapsed and refractory blood cancers, which are difficult to cure because their cells deploy strong protein "deflector shields" to neutralize the cell death signals that chemotherapy agents used against them initially, say the researchers.

The prototype compound, called a "stapled BIM BH3 peptide," is designed to disable the cancer's defenses by hitting a family of protein targets that regulate cell death.

In proof-of-concept studies in mice with transplanted, drug-resistant leukemia tumors, the compound alone suppressed cancer growth, and when paired with other drugs, showed synergistic anti-cancer activity, say researchers led by Loren Walensky, MD, PhD, of Dana-Farber/Children's Hospital Cancer Center.

Their paper has been posted online by the Journal of Clinical Investigation and will appear in the journal's June issue. Walensky is the senior author and James LaBelle, MD, PhD, is the first author.

A cell's "fate" when and whether it lives or dies depends on a tug-of-war between pro-death and anti-death forces within the cell that serve as a check-and-balance system to maintain orderly growth. The system is regulated by the BCL-2 family of proteins, which contains both pro-death and pro-survival members.

When cells are no longer needed or are damaged beyond repair, the body activates pro-death BCL-2 proteins to shut down mitochondria the power plants of the cell resulting in an orchestrated cellular destruction known as apoptosis, or programmed cell death.

Many cell-killing cancer treatments work by triggering these "executioner proteins" to cause tumor cells to commit suicide in this fashion. But cancer cells can escape their death sentence and even become immortal by hyperactivating the survival arm of the family; these proteins intercept the executioner proteins and block their lethal mission.

"When cancers recur, they activate not just one type of survival protein, but many," explains Walensky, whose laboratory has extensively studied the cell-death system and makes compounds to manipulate it for research and therapeutic purposes.

"It's as if relapsed cancers 'learned' from their initial exposure to chemotherapy such that when they come back, they put up a variety of formidable barriers to apoptosis," he adds. "To reactivate cell death in refractory hematologic cancers, we need new pharmacologic strategies that broadly target these obstacles and substantially lower the apoptotic threshold."

When cancers specifically rely on one or two survival proteins, treating them with selective BCL-2 inhibitors can be very effective at eliminating the cancer cells' survival advantage. But relapsed cancers often evade such agents by deploying a battery of alternate survival proteins, so what's needed, Walensky says, are "next-generation" compounds that can block a wider range of survival proteins without jeopardizing normal tissues.

In the current research, the scientists built a chemically-reinforced peptide containing the death-activating BH3 domain of an especially potent killer protein, BIM, which is able to tightly bind with and neutralize all of the BCL-2 family survival proteins. This 'stapled' peptide, which incorporates the natural structure and properties of BIM BH3, not only disables the survival proteins, but also directly activates pro-death BCL-2 family proteins in cancer cells, making them self-destruct. Importantly, non-cancerous cells and tissues were relatively unaffected by the treatment.

"The diversity of BCL-2 family survival proteins blunts the anti-tumor activity of essentially all cancer treatments to some degree," Walensky points out. "By using Nature's solution to broad targeting of the BCL-2 pathway with a stapled BIM BH3 peptide, our goal is to eliminate cancer's protective force field and enable the arsenal of cancer treatments to do their job."


'/>"/>

Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-632-5357
Dana-Farber Cancer Institute
Source:Eurekalert  

Related medicine news :

1. Strategy discovered to activate genes that suppress tumors and inhibit cancer
2. Discovery suggests new combination therapy strategy for basal-like breast cancers
3. White House Drug Policy Shifts Strategy
4. Scripps research scientists illuminate cancer cells survival strategy
5. Scientists report first step in strategy for cell replacement therapy in Parkinsons disease
6. Novel strategy stymies SARS et al.
7. UCSF tapped for US National AIDS Strategy initiative
8. Federal government releases environmental, health, and safety research strategy for nanotechnology
9. Miriam Hospital researchers pilot new acute hepatitis C screening strategy for HIV-infected patients
10. Strategy for improving health care for uninsured, low-income, and minorities in the US
11. New strategy likely to speed drug development for rare cancers
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New drug strategy attacks resistant leukemia and lymphoma
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... ... in many scientific laboratories. The assembly protocols involve many repetitive steps and often ... for automation, which enables the high-throughput needed, and results in a lower error ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... Hills of Pittsburgh now have easier access to the robotic-assisted total-hip and ... Health Network (AHN). Orthopaedic surgeons at Forbes Hospital and Jefferson Hospital recently ...
(Date:3/29/2017)... ... March 29, 2017 , ... AvePoint , the ... American office location in Richmond, Virginia, located at the Riverfront Plaza, 901 East Byrd ... Lieutenant Governor of Virginia Ralph S. Northam and Mayor of Richmond Levar M. Stoney. ...
(Date:3/28/2017)... CA (PRWEB) , ... March 28, 2017 , ... Tuesday, ... asking the American public to take the Diabetes Risk Test to find out if ... the Los Angeles World Airports will light up the evening sky by programming the ...
(Date:3/28/2017)... CARTERSVILLE, Georgia (PRWEB) , ... March 28, 2017 ... ... analyst to its award-winning team. Ruel Williamson brings his extensive knowledge of appraisals, ... been a leader in the real estate valuation industry for more than 40 ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... 2017 Varian Medical Systems (NYSE: VAR ... second quarter of fiscal year 2017 following the close of ... will be followed by a teleconference available to all interested ... link to the conference call webcast will be available on ... teleconference call and replay: ...
(Date:3/29/2017)... , March 29, 2017   Royal Philips ... in health technology, and PathAI, a company that ... with the aim to develop solutions that improve ... cancer and other diseases. The partnership aims to ... this form of artificial intelligence to be applied ...
(Date:3/29/2017)... , March 29, 2017 Neurim Pharmaceuticals ... Exeltis will obtain exclusive marketing rights for Neurim,s new Rx PedPRM ... ... targeted to treat sleep disorders in children with Autism Spectrum Disorders ... sleep medication approved for children. The collaboration with Exeltis ...
Breaking Medicine Technology: